CathVision – EP Recording. Enhanced.

CHANGING THE STANDARD

Traditional EP recording systems are expensive, limited in capability and deliver substandard electrogram signals, creating an unacceptable status quo that reduces the ability to effectively diagnose and determine therapy for complex cardiac arrhythmia.

EMPOWERING ELECTROPHYSIOLOGISTS WITH MODERN TECHNOLOGY

CathVision is committed to enhancing clinical decision making and patient outcomes in the EP lab through the advancement of EP recording technologies.

Learn More

THE ECGENIUS™ SYSTEM

CathVision’s innovative EP recording technology – the ECGenius™ System – is enhancing the quality of cardiac electrical signals to improve the diagnosis, characterization and treatment of the most common heart rhythm disorders.

Learn More

CARDIALYTICS™

Artificial Intelligence Analytics

CathVision is developing a suite of AI-based analytic tools – CARDIALYTICS™ – designed specifically to provide unprecedented levels of automated analyses during the diagnosis and treatment of complex atrial arrhythmia including atrial fibrillation.

Learn More

ADVANCING ARRHYTHMIA CARE

At CathVision, we are committed to the development of innovative technologies that provide electrophysiologists with unprecedented levels of automated analyses to improve the treatment of complex cardiac arrhythmia.

Learn More

1 / 5

Pristine data

See what you’ve been missing.

Precise Analytics

Real-time, automated, AI-based algorithms physicians can trust.

Powerful Decisions

Comprehensive, clinical decision-making simplified.

CathVision Secures $9 Million In Funding To Accelerate Adoption Of ECGenius System & CARDIALYTICS AI-Suite

CathVision announces a financing round of $9 million to help advance commercial operations driving adoption of the ECGenius™ System, and to support the continued development of artificial intelligence-powered analytic modules.

CathVision’s ECGenius System to be Featured at HRS 2023 Rhythm Symposium Theater and Scientific Presentations

CathVision announces an extensive slate of educational opportunities and scientific sessions at this year’s Heart Rhythm conference demonstrating the significant impact of the ECGenius™ System and potential benefits of AI-based analytics.

CathVision Announces Initiation of Clinical Study Evaluating Signal Complexity Algorithm

Study Advances Efforts to Launch CARDIALYTICS Suite of Analytic Tools

CathVision Announces Close Of $7.2 Million Financing Round

Funding Will Accelerate Commercialization of the ECGenius™ System and Expand Development of Analytic Modules

CathVision Announces FDA Clearance of ECGenius™ High-Fidelity, Low-Noise EP Recording Technology

ECGenius™ Sets a New Standard for ECG Signal Acquisition, Interpretation and Therapy Support

CathVision Announces Completion of Patient Enrollment at First U.S. Clinical Trial Evaluating High-Fidelity, Low-Noise EP Recording Technology

University of Vermont Medical Center Initiates Evaluation of the ECGenius™ System as CathVision Prepares for U.S. Launch

CathVision Announces First Patient Enrollments in PVISION Multicenter Clinical Study

Researchers to Examine Efficacy of Using AI Algorithm to Confirm Pulmonary Vein Isolation

CathVision Adds U.S. Profile to Its Board of Directors

CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, is announcing a change to its Board of Directors.

Previous slide

Next slide

EP RECORDING. ENHANCED.

It’s time to upgrade the EP lab.

The ECGenius™ System represents an evolution in cardiac signal acquisition, interpretation and therapy support, creating unprecedented opportunities for the integration of AI-based algorithms.

ABOUT CathVision

CathVision’s mission is to help physicians cure cardiac arrhythmia. Committed to empowering physicians to make more informed clinical decisions in the EP lab, CathVision is redefining the necessity of exceptional cardiac electrical signals to diagnose, characterize and treat the most common heart rhythm disorders. The company is focused on developing electrophysiology solutions centered around an innovative EP recording system and AI-based analytic tools.

CathVision began as a graduate-level clinical research project designed to determine necessary improvements to ablation therapy and was officially launched as a company in 2013 in Denmark. The company’s presence has since expanded to the United States with operations in Minnetonka, Minnesota.

history

May 2023

ECGenius System featured at HRS 2023 Rhythm Theater Symposium and scientific sessions.

April 2023

Patient enrollment of a follow-on clinical study to demonstrate the value of the Signal Complexity algorithm at OLV Hospital Aalst, led by Dr. Tom De Potter, begins.

MARCH 2023

CathVision announces key milestones in advance of ECGenius commercial launch.

November 2022

NYU Langone Health initiates clinical study evaluating the Signal Complexity™ algorithm.

August 2022

CathVision raises $7.2 million from existing investors to further the advancement of AI-powered analytics and commercialization of the ECGenius™ System

MAY 2022

The ECGenius™ System, CathVision’s unique high-fidelity, low-noise EP recording technology, earns FDA clearance.

APRIL 2022

CathVision enrolls patients in first U.S.-based clinical study at the University of Vermont Medical Center.

2021

CathVision enrolls first patients in PVISION Multicenter Clinical Study at four European hospitals.

2020

CathVision completes an investment round of €13M to begin multi-center clinical studies.

2019

CathVision expands its board of directors and is awarded a €2.2M grant from the Horizon 2020 programs.

2018

CathVision obtains IOS13485 certification and establishes a presence in the U.S.